Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles

Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles

The spread of coronavirus disease 2019 (COVID-19) throughout the world has resulted in stressful healthcare burdens and global health crises. Developing an effective measure to protect people from infection is an urgent need. The blockage of interaction between angiotensin-converting enzyme 2 (ACE2)...

Full description

Bibliographic Details
Main Authors:	Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, Mingjie Shi, Hong Qiu, Yongzhuo Huang
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	SARS-CoV-2 COVID-19 Spike protein Pseudovirus Extracellular vesicles ACE2
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383521003464

Similar Items

Herbo-mineral formulation, Divya-Swasari-Vati averts SARS-CoV-2 pseudovirus entry into human alveolar epithelial cells by interfering with spike protein-ACE 2 interaction and IL-6/TNF-α /NF-κB signaling
by: Acharya Balkrishna, et al.
Published: (2022-10-01)

Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus
by: Sang Ah Yi, et al.
Published: (2020-09-01)

SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
by: Masaud Shah, et al.
Published: (2022-01-01)

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]
by: Canhao Wu, et al.
Published: (2023-11-01)

Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
by: Jie Hu, et al.
Published: (2020-12-01)

A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay
by: Gaetano Donofrio, et al.
Published: (2021-04-01)

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
by: Jianhui Nie, et al.
Published: (2020-01-01)

Extracellular vesicles enclosed‐miR‐421 suppresses air pollution (PM2.5)‐induced cardiac dysfunction via ACE2 signalling
by: Hongyun Wang, et al.
Published: (2022-05-01)

A Novel and Secure Pseudovirus Reporter System Based Assay for Neutralizing and Enhancing Antibody Assay Against Marburg Virus
by: Jinhao Bi, et al.
Published: (2022-06-01)

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
by: Jeroen Pollet, et al.
Published: (2021-08-01)

Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2
by: Ariana Ghez Farrell, et al.
Published: (2022-09-01)

Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies
by: Zach Troyer, et al.
Published: (2021-06-01)

Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS‐CoV‐2 infection
by: Hark Kyun Kim, et al.
Published: (2022-01-01)

Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells
by: Hua-Long Xiong, et al.
Published: (2020-01-01)

Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol
by: Jose Manuel Condor Capcha, et al.
Published: (2021-01-01)

Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants
by: Hancong Sun, et al.
Published: (2022-06-01)

Generation of Spike-Extracellular Vesicles (S-EVs) as a Tool to Mimic SARS-CoV-2 Interaction with Host Cells
by: Roberta Verta, et al.
Published: (2022-01-01)

Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
by: Sheng-Wen Huang, et al.
Published: (2020-08-01)

Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles
by: Sheng Wang, et al.
Published: (2022-02-01)

Development of a Cell-Based SARS-CoV-2 Pseudovirus Neutralization Assay Using Imaging and Flow Cytometry Analysis
by: Jerilyn R. Izac, et al.
Published: (2023-08-01)

The development and application of pseudoviruses: assessment of SARS-CoV-2 pseudoviruses
by: Conglian Tan, et al.
Published: (2023-12-01)

WT1 and ACE mRNAs of blood extracellular vesicle as biomarkers of diabetic nephropathy
by: Ehsan Hashemi, et al.
Published: (2021-07-01)

Generation of JC Polyoma Pseudovirus for High-Throughput Measurement of Neutralizing Antibodies
by: Mami Matsuda, et al.
Published: (2024-01-01)

A simple and safe antibody neutralization assay based on polio pseudoviruses
by: Zheng Jiang, et al.
Published: (2019-02-01)

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
by: Markus Hoffmann, et al.
Published: (2022-06-01)

Antibiotics daptomycin interacts with S protein of SARS-CoV-2 to promote cell invasion of omicron (B1.1.529) pseudovirus
by: Xu Cao, et al.
Published: (2024-04-01)

A novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventions
by: Ssu-Hsueh Tseng, et al.
Published: (2021-04-01)

Expression of Endogenous Angiotensin-Converting Enzyme 2 in Human Induced Pluripotent Stem Cell-Derived Retinal Organoids
by: Henkie Isahwan Ahmad Mulyadi Lai, et al.
Published: (2021-01-01)

Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests
by: Sofie Wallerström, et al.
Published: (2014-01-01)

SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes
by: Raj Kalkeri, et al.
Published: (2021-08-01)

Development of a Bioluminescent Imaging Mouse Model for SARS-CoV-2 Infection Based on a Pseudovirus System
by: Xi Wu, et al.
Published: (2023-06-01)

Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS‐CoV‐2 Variants after Primary and Booster Immunization
by: Hui Xie, et al.
Published: (2022-04-01)

Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS‐CoV‐2
by: Xiaohang Chen, et al.
Published: (2022-12-01)

A method for the generation of pseudovirus particles bearing SARS coronavirus spike protein in high yields
by: Yoichiro Fujioka, et al.
Published: (2022-04-01)

Disrupting ACE2 Dimerization Mitigates the Infection by SARS-CoV-2 Pseudovirus
by: Jiaqi Zhu, et al.
Published: (2022-07-01)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
by: Qizhong Lu, et al.
Published: (2021-01-01)

Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10
by: Kelei Li, et al.
Published: (2020-06-01)

Immunomodulatory properties of Leishmania tarentolae extracellular vesicles containing the Spike protein of SARS-CoV-2
by: Ana Catalina Medina, et al.
Published: (2024-04-01)

Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection
by: Hao Sun, et al.
Published: (2021-01-01)

Small Structural Proteins E and M Render the SARS-CoV-2 Pseudovirus More Infectious and Reveal the Phenotype of Natural Viral Variants
by: Hsin-I Wang, et al.
Published: (2021-08-01)